Exhibit
10.1


LICENSE AGREEMENT


This License Agreement (“Agreement”) is effective and
entered into as of _____, 2006 (the “Effective Date”), by and between GE
Healthcare AS., (“GEHC”), a Norwegian corporation with offices at  Nycoveien 1-2 Postboks 4220 Nydalen, Oslo
Norway and Acusphere Inc. (“ACUS”) a Delaware corporation  with offices at 500 Arsenal St., Watertown,
MA 02472.  (GEHC and ACUS collectively “the
Parties”).


WHEREAS, GEHC owns certain patents relating to the
compositions, methods of preparing, and methods of use of ultrasound contrast
agents;


WHEREAS, ACUS is developing that certain ultrasound
contrast agent, AI-700, which is the subject of 
Investigational New Drug Application (“INDA”) with the U.S. Food and
Drug Administration;


WHEREAS, ACUS desires to obtain a non-exclusive
license to certain of GEHC’s patents.


 NOW, THEREFORE,
in consideration of the foregoing and the covenants, acknowledgements and
representations contained in this Agreement, the Parties hereby agree as
follows:


ARTICLE
I.  DEFINITIONS


1.1.          Definitions.  For purposes of this Agreement, the terms
defined here shall have the meanings specified below.  These terms are intended to encompass both
singular and plural forms.


1.1.1.                     “Affiliate” shall mean an
entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with a Party.  Without limiting the generality of the
foregoing, “control” shall mean the ownership, directly or indirectly, of fifty
percent (50%) or more of the issued share capital or shares of stock entitled
to vote for the election of directors, in the case of a corporation, or fifty
percent (50%) or more of the equity interests in the case of any other entity
or the legal power to direct or cause the direction of the general management
and policies of the entity in question.


1.1.2.                     “AI-700” shall mean the
ultrasound contrast product currently under development by ACUS and for which
ACUS has filed an INDA.  The term “AI-700”
includes postapproval changes made to the product  in accordance with Section 506A of the
federal Food, Drug, and Cosmetic Act and Section 314.70 (21 CFR 314.70) as
recommended in the document: GUIDANCE FOR INDUSTRY, CHANGES TO AN APPROVED NDA
OR ANDA, April 2004, U.S. Department of Health 



 1
 






 



                                                and
Human Services, Food and Drug Administration, Center for Drug Evaluation and
research (CDER), April 2004, CMC, Revision 1.


1.1.3.                     “Field” shall mean
ultrasound diagnostic imaging in humans and animals.


1.1.4.                     “GEHC Licensed Patents”
shall mean (i) all present patents and patent applications worldwide that claim
the composition of, manufacture of, or methods of use of ultrasound contrast
agents, which are issued or pending as of the Effective Date, together with all
future patents and patent applications that claim priority (directly or
indirectly through other applications) to any patent or patent application
pending as of or before the Effective Date that are owned by or licensed to
GEHC or an Affiliate with a right to sublicense, including without limitation,
those listed on Exhibit A hereto and (ii) all patents and patent applications
worldwide that claim the composition of, manufacture of, or methods of use of
ultrasound contrast agents which GEHC or an Affiliate acquires (by license with
a right to sublicense, acquisition or otherwise (including by internal
invention)) within 12 months after the Effective Date.


1.1.5.                      “Territory” shall mean the
entire world except Japan, the People’s Republic of China, and the Republic of
Korea.


1.1.6.                     “Third Party” shall mean
any entity other than GEHC, ACUS, or their respective Affiliates.


ARTICLE II. 
LICENSE FROM GEHC TO ACUS


2.1.            Subject to the terms and obligations of this
Agreement GEHC hereby grants ACUS, and ACUS accepts, a nonexclusive license
under the GEHC Licensed Patents to make, use, sell, offer to sell, and import
AI-700 in the Field in the Territory.


2.2.          ACUS has the right
to grant distribution rights for AI-700 under the GEHC Licensed Patents and has
the limited right to grant sublicenses to manufacturers to manufacture AI-700
on behalf of ACUS, as well as to its distributors in connection with their
distribution rights.


2.3.          Other than the
limited right to sublicense granted in paragraph 2.2, ACUS does not have the
right to grant sublicenses.


2.4.          The Parties
acknowledge that nothing in this Agreement shall be construed to convey any
title or ownership rights to the GEHC Licensed Patents.  With the exception of the rights explicitly
granted in paragraphs 2.1 through 2.2, no license, or other right, title or
interest to or under the GEHC Licensed Patents is granted by implication,
estoppel or otherwise.



 2
 






 



 


2.5.          To the extent required by and in conformance
with any applicable laws, ACUS shall mark AI-700 with the numbers of the
applicable GEHC Licensed Patents.


ARTICLE
III.  RELEASE AND COVENANT NOT TO SUE


3.1.          GEHC hereby releases
ACUS and its current Affiliates from all claims, allegations, damages,
obligations, liabilities or expenses of any kind or nature that it may have
against any of them, subject to the limitation of paragraph 3.3.  This releases all claims and obligations
resulting from anything which has happened up to now, including claims of which
GEHC is not aware, and specifically including without limitation all claims or
infringement of GEHC Licensed Patents on account of the manufacture, use, sale,
offer for sale, and importation of AI-700 up to and including the Effective
Date.


3.2.          ACUS hereby releases
GEHC and its current Affiliates from all claims, allegations, damages, obligations,
liabilities or expenses of any kind or nature that it may have against any of
them.  This releases all claims and
obligations resulting from anything which has happened up to now, including
claims of which ACUS is not aware, and specifically including without
limitation all claims or infringement of any ACUS patent on account of the
manufacture, use, sale, offer for sale, and importation of ultrasound contrast
agents up to and including the Effective Date.


3.3.          None of the releases
above shall be construed in any way as being a release of any indebtedness to
any GEHC Affiliate under any loan agreement, security interest, agreement of
indebtedness, security interest, or other agreement for the loan of money,
extension of credit, provision of services, or sale or lease of goods.


3.4.          To the extent that
it may apply to Agreement, the parties waive any and all rights under
California Civil Code § 1542 (as well as any similar statute or law in any
other jurisdiction), which section has been duly explained to each of the
parties by their respective counsel, and which reads as follows: “A general
release does not extend to claims which the creditor does not know or suspect
to exist in his favor at the time of executing the release, which if known by
him must have materially affected his settlement with the debtor.”


3.5.          ACUS, for itself and
its current and future Affiliates, covenants not to sue GEHC or its Affiliates
for infringement of any patent on account of GEHC or its Affiliates’
manufacture, use, sale, or offer to sell of Optison or Sonazoid in the
Territory for use in the Field.  This
covenant shall extend to GEHC’s distributors and customers on account of their
purchase, sale, or use of Sonazoid or Optison in the Territory for use in the
Field.


3.6           GEHC, for itself and its current and
future Affiliates, covenants not to sue ACUS or its Affiliates for infringement
of any patent on account of ACUS or its Affiliates’ manufacture, use, sale, or
offer to sell AI-700 in the Territory for use in the Field.  This covenant shall extend to ACUS’s
distributors and customers on account of their purchase, sale, or use of AI-700
in the Territory for use in the Field.



 3
 






 



3.7           It
is the intention of the parties to settle current and potential intellectual
property disputes pertaining to the GEHC Licensed Patents and patents that ACUS
has in the Field. In that connection, the parties shall:


3.7.1.                     withdraw
all current oppositions brought against the other’s patents for the Field in
countries foreign to the United States;


3.7.2.                     refrain
from filing any future opposition or other challenge against the claims of each
other’s patents relating to Optison, Sonazoid or AI-700  in countries foreign to the United States;
and


3.7.3.                     refrain
from filing any requests for interference, reexamination, protest or other
challenge against the claims of each other’s patents relating Optison, Sonazoid
or AI-700  in the United States.


ARTICLE IV. 
FEES, PAYMENTS, WARRANTIES, INDEMNIFICATION


4.1.          In consideration of
the licenses and release granted in Section 3, ACUS shall make the following
payments to GEHC:


4.1.1.                     An upfront
license fee of $10,000,000 paid in two installments of:


a)     $5,000,000 within five business days after
execution of this Agreement.


b)    $5,000,000 on the first anniversary of the
Effective Date,


said fees to be non-contingent and
non-returnable.


4.1.2.                     A license fee
of $10,000,000 paid in two installments of:


a)     $5,000,000 within five business days after
the earlier of (i) receipt of regulatory approval by the U.S. Food and Drug
Administration to market AI-700 or (ii) the approval of a Marketing
Authorization Application in Europe related to AI-700.


b)    $5,000,000 upon the one year anniversary of
the payment set forth in paragraph 4.1.2(a),


said fees to
be non-returnable.


4.2.          All payments by ACUS
to GEHC shall be by wire transfer of same day federal funds to the following
account (or any alternative account which GEHC designates to ACUS prior to the
due date of any of the payments set forth in paragraph 4.1).


Bank Name: BNP Paribas
London Branch


Name on Account: 
Amersham Health AS



 4
 






 



SWIFT-BIC: BNPAGB22


IBAN: GS89 BNPA23463574
375010


Account No.  
09678 074375 00191


4.3.          Any payments made under Section 4 of
this Agreement are inclusive of any tax imposed upon such payments.  In addition, in the event any of the payments
made by ACUS pursuant to Section 4 are subject to withholding taxes under
the laws of any jurisdiction, ACUS shall consult GEHC in advance and take all
reasonable actions, on a timely basis, to reduce the level of withholding to
the minimum permitted under the laws of the jurisdiction having regard to the
terms of any relevant double tax treaty. Should a withholding tax still be due,
such amounts payable to GEHC shall be reduced by the amount of taxes deducted
and withheld, and ACUS shall pay the amounts of such taxes to the proper
governmental authority in a timely manner and promptly transmit to GEHC an
official tax certificate or other evidence of such tax obligations together
with proof of payment from the relevant governmental authority of all amounts
deducted and withheld sufficient to enable GEHC to claim such payment of
taxes.  ACUS will provide GEHC with
reasonable assistance to enable GEHC to recover such taxes as permitted by law.


4.4.          All payments under any provision of
this Agreement shall bear interest from the date due until paid at a rate equal
to the lesser of (i) five percentage points above the prime rate of Citibank, N.A. (or its successor) in New
York, New York, as announced on the date such payment was due, or (ii)
the highest amount allowable by law, compounded monthly.  In addition, ACUS shall reimburse GEHC for
all reasonable costs and expenses, including without limitation reasonable
attorneys’ fees and legal expenses, incurred in the collection of late or
missed payments.


4.5.          Each Party shall bear its own costs
and expenses, including, without limitation, its attorneys fees, relating to
any action to be taken or having been taken in respect to this Agreement.


4.6.          Each Party makes the following
warranties and representations to the other Party:


4.6.1.                     each Party is a corporation duly
organized and validly existing and in good standing under the laws of the state
or country in which it is organized and has all requisite power and authority
to enter into and perform this Agreement and the transactions contemplated
hereby and to require its Affiliates to abide by its terms and conditions;


4.6.2.                     all requisite corporate action on
the part of each Party has been completed for the authorization of the
execution and delivery of this Agreement and the performance of the transaction
contemplated hereunder;



 5
 






 



4.6.3.                     this Agreement is, and such other
transactions will be, valid and binding obligations of each Party enforceable
in accordance with their respective terms; and


4.6.4.                     the execution, delivery and
performance of this Agreement and the consummation of transactions contemplated
hereby do not and will not violate the provisions of any Party’s certificate of
incorporation or bylaws or similar type documents or the provisions of any
note, indenture, lease, license permit or other instrument or obligation or
violate any law, order, rule or regulation applicable to it.


4.7.          Nothing in this Agreement shall be construed as a warranty
or representation by GEHC as to the validity of any GEHC Licensed Patent or
that AI-700 is free from infringement of domestic or foreign patents or other
proprietary interests of other parties. GEHC IS LICENSING THE GEHC LICENSED
PATENTS TO ACUS ON AN “AS IS” BASIS. 
GEHC MAKES NO WARRANTIES EITHER EXPRESS OR IMPLIED OF ANY KIND, AND
HEREBY EXPRESSLY DISCLAIMS ANY WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY
KIND AS TO THE GEHC LICENSED PATENTS, THE SUBJECT OF ANY LICENSE HEREUNDER
AND/OR ANY PRODUCTS, INCLUDING BUT NOT LIMITED TO, ANY WARRANTIES OF
MERCHANTABILITY, FITNESS, ADEQUACY OR SUITABILITY FOR A PARTICULAR PURPOSE, USE
OR RESULT, AND ANY WARRANTIES OF FREEDOM OF INFRINGEMENT OF ANY PATENTS,
COPYRIGHTS, TRADE SECRETS OR OTHER PROPRIETARY RIGHTS.  NEITHER GEHC, NOR ANY EMPLOYEE OR AGENT OF
GEHC, SHALL HAVE ANY LIABILITY TO ACUS, ITS AFFILIATES, OR SUBLICENSEES, OR ANY
OTHER PERSON ARISING OUT OF THE USE OF GEHC LICENSED PATENTS OR PRODUCTS
INCLUDING BUT NOT LIMITED TO THE LACK OF MERCHANTABILITY, INADEQUACY OR
UNSUITABILITY OF THE GEHC LICENSED PATENTS OR PRODUCTS FOR ANY PARTICULAR
PURPOSE OR TO PRODUCE ANY PARTICULAR RESULT, OR FOR ANY LATENT DEFECTS THEREIN.


4.8.          ACUS shall indemnify
and hold GEHC and its Affiliates harmless against any and all third-party
actions, suits, claims, demands, prosecutions, liabilities, costs, expenses,
damages, deficiencies, loss or obligations (including reasonable attorneys’
fees) based on or arising out of this Agreement, including, without limitation,
(i) the development, manufacture, packaging, use, or sale of AI-700 (ii) the
practice of the GEHC Licensed Patents by ACUS, its Affiliates, its Sublicensees
or its (or their) customers and (iii) any representation made or warranty given
by ACUS, its Affiliates with respect to GEHC Licensed Patents or AI-700.


4.9.          ACUS shall maintain, during the term of this
Agreement, commercial general liability insurance, including product liability
insurance, with reputable and financially secure insurance carriers, on
commercially reasonable and prudent terms and limits.


4.10.        ACUS and its current and future Affiliates
shall not directly or indirectly challenge or induce any Third Party to
challenge the validity or enforceability of the GEHC Licensed Patents, or any
patent claim(s) therein, or initiate or participate in any re-examination or
other proceeding related to the validity, enforceability or patentability of
any 



 6
 






 



claim
of the GEHC Licensed Patents before any tribunal or patent office.  This section shall not prohibit ACUS and its
Affiliates from responding to a subpoena, process, or discovery requests in any
litigation or administrative proceeding provided that ACUS gives prompt notice
to GEHC of the receipt of said subpoena, process or discovery requests.


ARTICLE V. 
DURATION


5.1.          The term of the licenses
granted by GEHC shall be until the last to expire of the GEHC Licensed Patents.


ARTICLE
VI.  CONFIDENTIALITY


6.1.          No
Party shall disclose the contents of this Agreement to any other person or
entity and each Party shall retain in confidence the terms and conditions of
this Agreement, except as necessary to comply with law or the valid order of a
court or agency of competent jurisdiction of a state or federal authority; or
to the extent necessary in any action, suit or proceeding to enforce this Agreement;
or to their respective Affiliates, banks, auditors, accountants, lawyers, and
any other representative of a Party who has a good faith need to know, provided
that any such person or entity to whom disclosure is made must be advised of
the confidentiality of the information disclosed and agree to keep such
information confidential.


6.2.          No public statements
of any kind pertaining to this Agreement may be made except as required by law,
such as that enforced by the Securities Exchange Commission of the United
States of America, unless the parties otherwise mutually agree in writing.  Attached hereto as Exhibit __is a form of
press release that the parties agree shall be issued by ACUS  promptly after the execution of this
Agreement.


ARTICLE VII. 
MISCELLANEOUS


7.1.          Notice:  All notices or communications required
pursuant to this Agreement shall be in writing and shall be deemed to have been
duly given upon the date of receipt if delivered by hand, international
overnight courier, confirmed facsimile transmission, or registered or certified
mail (return receipt requested, postage prepaid) to the following addresses or
facsimile numbers:


	
  For GEHC:

  	
   

  	
   

  	
  GE Healthcare AS.

  	
   

  
	
   

  	
  c/o GE
  Healthcare

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Nycoveien 1-2
  Postboks 4220

  	
   

  
	
   

  	
  Nycalen, Oslo
  Norway

  	
   

  
	
   

  	
  Attn: General
  Counsel

  	
   

  
	
   

  	
  Fax:
  47-2222-9865

  	
   

  
	
   

  	
   

  	
   

  
	
  For ACUS:

  	
   

  	
   

  	
  Sherri Oberg

  	
   

  	
   

  	
   

  
	
   

  	
  Acusphere Inc.

  	
   

  	
   

  	
   

  
	
   

  	
  500 Arsenal Street

  	
   

  	
   

  	
   

  
													



 



 7
 






 



 


	
  

  	
  Watertown, MA 02472

  	
   

  	
   

  	
   

  
	
   

  	
  FAX 617-926-3605

  	
   

  	
   

  	
   

  
							



 


7.2.          Choice of Law and
Forum:  The Parties agree that this
Agreement shall be governed by the laws of the State of New York without
reference to its conflict of laws principles. 
Any legal action or proceeding arising out of or in connection with this
Agreement or other aspect of the Parties’ relationship shall be brought only in
the state or federal courts located in New York County, New York, and each
Party hereby consents to the jurisdiction of such courts for any such matter.


7.3.          Entire Agreement:  This Agreement sets forth all the licenses, covenants,
promises, agreements, warranties, representations, conditions, and
understandings between the Parties hereto and supersede all prior agreements
and understandings between the Parties relating to the subject matter hereof.  This Agreement, including, without
limitation, the Exhibits attached hereto, is intended to define the full extent
of the legally enforceable undertakings of the Parties hereto.


7.4.          Severability:  In the event that any provision of this
Agreement shall, for any reason, be held to be invalid or unenforceable in any
respect, such invalidity or unenforceability shall not affect any other
provision hereof, and the Parties shall negotiate in good faith to modify the
Agreement to preserve their original intent.


7.5.          Amendment and Waiver:  This Agreement may be amended, supplemented,
or otherwise modified only by means of a written instrument signed by all
Parties.  Any waiver of any rights or
failure to act in a specific instance shall relate only to such instance and
shall not be construed as an agreement to waive any rights or fail to act in
any other instance, whether or not similar.


7.6.          Breach and Cure: 
Either party shall have the right to cure its material breach.  The cure shall be effected within a
reasonable period of time but in no event later than twenty (20) days after
notice of any breach given by the non-breaching party, or five (5) business
days in the event of a payment obligation.


7.7.          Headings:  The sections and paragraphs headings
contained herein are for the purposes of convenience only and are not intended
to define or limit the contents of said sections or paragraphs.


7.8.          Counterparts:  This Agreement may be signed in counterpart,
each of which shall be deemed to be an original.  Signatures shall be provided by facsimile
transmission, with original signatures following by mail.


7.9.          Assignment:  ACUS may not assign this Agreement nor the
licenses granted herein to any Third Party unless said assignment is to a
successor by merger, acquisition, or corporate reorganization, and/or in
connection with the sale or other disposition by license, joint venture or
otherwise of the entire business unit or product(s) to which this Agreement
pertains and assignee must agree to the terms of this Agreement on behalf of
itself and its Affiliates, including but not limited to the provisions of  paragraphs 3.5 and 4.10.  For 



 8
 






 



avoidance of doubt, the release of paragraph 3.1 shall not extend to
the assignee’s business or assets other than those acquired from ACUS.


7.10.        Subsequent Acquisitions:  If, after the Effective Date, ACUS or an
Affiliate either acquires an entity or acquires substantially all of the assets
from an entity, and said entity is, immediately prior to the date of
acquisition, licensed by the other party (“Licensor”) under one or more GEHC
Licensed Patents through an existing agreement pursuant to which royalties or
other payments are made by said entity to Licensor, then the license and other
rights granted herein to the Acquiring Party with respect to said GEHC Licensed
Patents shall apply to products manufactured by said entity or through the use
of said assets, provided that such royalties or other payments shall continue
to be made by the Acquiring Party or said entity to the Licensor with respect
to such products notwithstanding that the Acquiring Party may have been
licensed for the same products before the acquisition.  For avoidance of doubt, the release of
paragraph 3.1 shall not extend to any entity whose assets are acquired or
substantially acquired by ACUS.


IN WITNESS WHEREOF, the undersigned Parties have duly
executed and delivered this Agreement as of the date first written above.




	
  GE Healthcare AS.

  	
   

  	
  Acusphere, Inc.

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
  Title:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
   

  	
   

  	
  Date:

  	
   

  
	
   

  	
   

  	
   

  
							






 


 



 9














 


SCHEDULE A


	
  Title

  	
   

  	
   

  	
   

  	
  Country

  	
   

  	
  Patent No.

  	
   

  	
  Application No.

  
	
  Diagnostic and contrast
  agent

  	
   

  	
  US

  	
   

  	
  5618514

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  6544496

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  5670135

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  CH

  	
   

  	
  0576519

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  69231794.5

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  2156109

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0576519

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0576519

  	
   

  	
   

  
	
   

  	
   

  	
  HK

  	
   

  	
  1004980

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0576519

  	
   

  	
   

  
	
   

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  19933431

  
	
   

  	
   

  	
  US

  	
   

  	
  5536490

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  08/470044

  
	
   

  	
   

  	
  US

  	
   

  	
  6106806

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5567413

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/449832

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  DE

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0831926

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6217850

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  AT

  	
   

  	
  E238072

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
  726503

  	
   

  	
   

  
	
   

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
  PI1100844.0

  
	
   

  	
   

  	
  CZ

  	
   

  	
  293986

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  HK

  	
   

  	
  HK1014872

  	
   

  	
   

  
	
   

  	
   

  	
  IE

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  IL

  	
   

  	
  125748

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  NL

  	
   

  	
  0881915

  	
   

  	
   

  



 



 10
 






 



 


	
   

  	
   

  	
  NO

  	
   

  	
  318875

  	
   

  	
   

  
	
   

  	
   

  	
  PH

  	
   

  	
  1997-55604

  	
   

  	
   

  
	
   

  	
   

  	
  PT

  	
   

  	
  0881915

  	
   

  	
   

  
	
   

  	
   

  	
  RU

  	
   

  	
  001135

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6221337

  	
   

  	
   

  
	
   

  	
   

  	
  ZA

  	
   

  	
  97/1408

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  THERMALLY STABILIZED
  CONTRAST AGENT

  	
   

  	
  DE

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0885016

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6165442

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6562320

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  PROCESS FOR PREPARATION
  OF VESICLES

  	
   

  	
  DE

  	
   

  	
  69806020.2

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  1007102

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1005391

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1007102

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  1007102

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6444193

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6509004

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  AT

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
  701817

  	
   

  	
   

  
	
   

  	
   

  	
  BE

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
  2107107

  	
   

  	
   

  
	
   

  	
   

  	
  CH

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  P69222037.2

  	
   

  	
   

  
	
   

  	
   

  	
  DK

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  2106857

  	
   

  	
   

  
	
   

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
  934227

  
	
   

  	
   

  	
  FR

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  GR

  	
   

  	
  20040401146

  	
   

  	
   

  
	
   

  	
   

  	
  HK

  	
   

  	
  1002624

  	
   

  	
   

  
	
   

  	
   

  	
  IE

  	
   

  	
  82203

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  LU

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  MC

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  NL

  	
   

  	
  0576521

  	
   

  	
   

  
	
   

  	
   

  	
  NO

  	
   

  	
  307448

  	
   

  	
   

  
	
   

  	
   

  	
  SE

  	
   

  	
  0576521

  	
   

  	
   

  



 



 11
 






 



 


	
   

  	
   

  	
  US

  	
   

  	
  5529766

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  11/055543

  



 



 12
 






 



 


	
  METHOD FOR INFUSION OF
  ULTRASOUND

  	
   

  	
  AU

  	
   

  	
  770389

  	
   

  	
   

  
	
  CONTRAST AGENTS

  	
   

  	
  DE

  	
   

  	
  60006683.5

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1206286

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  1206286

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  1206286

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  1206286

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  1206286

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRATED STABILIZED
  MICROBUBBLE-TYPE ULTRASONIC IMAGING AGENT AND METHOD OF PRODUCTION

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  139577

  
	
   

  	
   

  	
  DK

  	
   

  	
  173528

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  4844882

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
  603718

  	
   

  	
   

  
	
   

  	
   

  	
  AT

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
  BE

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  P3885730.8

  	
   

  	
   

  
	
   

  	
   

  	
  CH

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0324938

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  METHODS FOR SELECTING
  AND USING GASES AS ULTRASOUND CONTRAST MEDIA

  	
   

  	
  AT

  	
   

  	
  E191346

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  2006200108

  
	
   

  	
   

  	
  BE

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  BR

  	
   

  	
  PI1100168.2

  	
   

  	
   

  
	
   

  	
   

  	
  BR

  	
   

  	
  PI1100167.4

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
  2119129

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
  2273140

  	
   

  	
   

  
	
   

  	
   

  	
  CH

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  CL

  	
   

  	
  40380

  	
   

  	
   

  
	
   

  	
   

  	
  CZ

  	
   

  	
  286149

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  69230885

  	
   

  	
   

  
	
   

  	
   

  	
  DK

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
  941242

  
	
   

  	
   

  	
  FR

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  GR

  	
   

  	
  3033908

  	
   

  	
   

  



 



 13
 






 



 


	
   

  	
   

  	
  HK

  	
   

  	
  HK1012564

  	
   

  	
   

  
	
   

  	
   

  	
  HU

  	
   

  	
  218018

  	
   

  	
   

  
	
   

  	
   

  	
  ID

  	
   

  	
  ID0014883

  	
   

  	
   

  
	
   

  	
   

  	
  IE

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  IL

  	
   

  	
  103120

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  LU

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  MC

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  MX

  	
   

  	
  182912

  	
   

  	
   

  
	
   

  	
   

  	
  MY

  	
   

  	
  MY/111060

  	
   

  	
   

  
	
   

  	
   

  	
  NL

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  NO

  	
   

  	
  313577

  	
   

  	
   

  
	
   

  	
   

  	
  NZ

  	
   

  	
  244341

  	
   

  	
   

  
	
   

  	
   

  	
  PL

  	
   

  	
  173817

  	
   

  	
   

  
	
   

  	
   

  	
  PT

  	
   

  	
  100867

  	
   

  	
   

  
	
   

  	
   

  	
  RU

  	
   

  	
  2114637

  	
   

  	
   

  
	
   

  	
   

  	
  SE

  	
   

  	
  0605477

  	
   

  	
   

  
	
   

  	
   

  	
  SG

  	
   

  	
  54121

  	
   

  	
   

  
	
   

  	
   

  	
  TW

  	
   

  	
  63126

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5573751

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5393524

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5409688

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5558094

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6723303

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5558854

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6156292

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6875420

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6620404

  	
   

  	
   

  
	
   

  	
   

  	
  ZA

  	
   

  	
  92/7114

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ULTRASOUND IMAGING OF
  TISSUE PERFUSION BY PULSE ENERGY DISRUPTION

  	
   

  	
  US

  	
   

  	
  6315730

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  US

  	
   

  	
  6595925

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ULTRASONOGRAPHY OF THE
  PROSTATE

  	
   

  	
  DE

  	
   

  	
  69831353.4

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1039833

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  1039833

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  1039833

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  1039833

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  1039833

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6428479

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6689065

  	
   

  	
   

  



 



 14
 






 



 


	
  IMPROVEMENTS IN OR
  RELATING TO ULTRASONOGRAPHY

  	
   

  	
  US

  	
   

  	
  6409671

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  PHASE SHIFT COLLOIDS AS
  ULTRASOUND CONTRAST AGENTS

  	
   

  	
  AU

  	
   

  	
  680652

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
  710508

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
  2154590

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0680341

  	
   

  	
   

  
	
   

  	
   

  	
  PL

  	
   

  	
  176870

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5595723

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5707607

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5876696

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5558853

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6569404

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6245319

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5558855

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5707606

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  GAS-FILLED MICROSPHERES
  WITH FLUORINE-CONTAINING SHELLS

  	
   

  	
  AU

  	
   

  	
  703652

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  2196599

  
	
   

  	
   

  	
  DE

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0769969

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5562893

  	
   

  	
   

  



 



 15
 






 



 


	
  USE OF PRESSURE
  RESISTANT PROTEIN MICROSPHERES ENCAPSULATING GASES AS ULTRASONIC IMAGING
  AGENTS FOR VASCULAR PERFUSION

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  2253734

  
	
   

  	
   

  	
  DE

  	
   

  	
  69732568.7

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0907380

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0907380

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0907380

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0907380

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0907380

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5976501

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  SENTINEL LYMPH NODE
  DETECTION

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  2003272154

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/530094

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRAST AGENTS FOR
  ULTRASONIC IMAGING

  	
   

  	
  AT

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  AU

  	
   

  	
  575735

  	
   

  	
   

  
	
   

  	
   

  	
  BE

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  CA

  	
   

  	
  1274773

  	
   

  	
   

  
	
   

  	
   

  	
  CH

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  NL

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
  SE

  	
   

  	
  0224934

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRAST AGENTS
  CONSISTING OF GALACTOSE PARTICLES AND AN AMPHIPHILIC CARBOXYLIC ACID

  	
   

  	
  DE

  	
   

  	
  P69319888.5

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0620743

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5567412

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5614169

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR RELATING
  TO CONTRAST AGENTS

  	
   

  	
  CA

  	
   

  	
  2127705

  	
   

  	
   

  



 



 16
 






 



 


	
   

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
  99203253.2

  
	
   

  	
   

  	
  US

  	
   

  	
  5558856

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5827502

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  11/055544

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN
  CONTRAST AGENTS, CONSISTING OF GALACTOSE PARTICLES

  	
   

  	
  US

  	
   

  	
  5637289

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5648062

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5928626

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  DE

  	
   

  	
  P69326447.0

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0627942

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0627942

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0627942

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5795562

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5674468

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5676925

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  US

  	
   

  	
  5718884

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  DE

  	
   

  	
  P69425136.4

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0689461

  	
   

  	
   

  



 



 17
 






 



 


	
  MEDICAL USE OF ORGANIC
  AEROGELS AND BIODEGRADABLE ORGANIC AEROGELS

  	
   

  	
  DE

  	
   

  	
  69425573.4

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0707474

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0707474

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  POLYMERIC
  SURFACTANT-ENCAPSULATED MICROBUBBLES AND THEIR USE IN ULTRASOUND IMAGING

  	
   

  	
  DE

  	
   

  	
  69430432.8

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0717658

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0717658

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0717658

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0717658

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0717658

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5919434

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5990263

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  US

  	
   

  	
  6274120

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  DE

  	
   

  	
  69526093.6

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  0779821

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  0779821

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  0779821

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0779821

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  0779821

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO ULTRASOUND IMAGING

  	
   

  	
  US

  	
   

  	
  5980460

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  5601085

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS

  	
   

  	
  EP

  	
   

  	
  0973552

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  0973552

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6264917

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6261537

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/722075

  



 



 18
 






 



 


	
  IMPROVEMENTS IN OR
  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS

  	
   

  	
  US

  	
   

  	
  6331289

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6680047

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRAST AGENTS CONTAINING
  TWO TYPES OF GAS FILLED MICROBUBBLES

  	
   

  	
  US

  	
   

  	
  6054118

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS

  	
   

  	
  US

  	
   

  	
  6548048

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  IMPROVEMENTS IN OR
  RELATING TO CONTRAST AGENTS

  	
   

  	
  AU

  	
   

  	
  745047

  	
   

  	
   

  
	
   

  	
   

  	
  DE

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  ES

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  FR

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  GB

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  HU

  	
   

  	
  224218

  	
   

  	
   

  
	
   

  	
   

  	
  IT

  	
   

  	
  1007100

  	
   

  	
   

  
	
   

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
  9903664

  
	
   

  	
   

  	
  US

  	
   

  	
  6375931

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
  6783752

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRAST AGENTS
  COMPRISING AN AZEOTROPIC MIXTURE OF TWO GASES FOR ULTRASOUND INVESTIGATIONS

  	
   

  	
  US

  	
   

  	
  6177061

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ULTRASOUND IMAGING WITH
  CONTRAST AGENT TARGETED TO MICROVASCULATURE AND A VASODILATOR DRUG

  	
   

  	
  US

  	
   

  	
  6811766

  	
   

  	
   

  
	
   

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/867237

  



 



 19
 






 



 


	
  APPARATUS HAVING
  PARTIALLY GOLD-PLATED SURFACE

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/761967

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  ULTRASOUND CONTRAST
  AGENT DISPERSIONS COMPRISING GAS AND DESTABILISING AGENT

  	
   

  	
  DE

  	
   

  	
  69921317.7

  	
   

  	
   

  
	
   

  	
   

  	
  EP

  	
   

  	
  1079865

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  CONTRAST AGENTS

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  10/717196

  



 


 



 20